ArticleRadiation oncology (London, England)2016

Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.

M Ritter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.